Biopsy Devices Market Report Scope & Overview:

The Biopsy Devices Market size is valued at USD 2.73 Billion in 2025 and is projected to reach USD 5.08 Billion by 2035, growing at a CAGR of 6.52% during the forecast period 2026–2035.

The Biopsy Devices Market analysis report provides a comprehensive overview of market dynamics, technological innovations, and its usage applications. Rising cancer incidence, increasing demand for minimally invasive diagnostic procedures, growing adoption of image-guided techniques, and expanding healthcare infrastructure are fuelling strong market growth during 2026–2035.

Global biopsy devices revenue exceeded USD 2.03 billion in 2025, driven by advanced healthcare systems and high cancer screening rates, MRI-guided biopsy devices.

Market Size and Forecast:

• Market Size in 2025: USD 2.73 Billion

• Market Size by 2035: USD 5.08 Billion

• CAGR: 6.52% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

To Get more information on Biopsy Devices Market - Request Free Sample Report

Biopsy Devices Market Trends:

• Artificial intelligence is increasingly used in biopsy guidance systems to improve accuracy and reduce false negatives.

• Vacuum-Assisted Biopsy (VAB) is Growing adoption due to minimally invasive procedures and better tissue yield.

• Nearly 63% of oncology diagnostic confirmations rely on biopsy results, making biopsy devices essential in cancer care.

• Increasing demand for accurate tissue sampling to guide targeted therapies and precision medicines.

• Emerging markets (Asia-Pacific, Latin America) are investing heavily in diagnostic centres and advanced imaging.

• Breast and prostate cancer screening initiatives are boosting biopsy volumes globally by Government.

U.S. Biopsy Devices Market Insights:

The U.S. Biopsy Devices Market has been valued at USD 0.95 Billion in 2025 and is expected to reach USD 1.62 Billion in 2035, growing at a CAGR of 5.62% from 2026 to 2035. The market is driven by the high prevalence of cancer, well-developed healthcare infrastructure, and the acceptance of minimally invasive, image-guided biopsy procedures.

Biopsy Devices Market Growth Drivers:

• Rising cancer incidence and growing demand for minimally invasive diagnostics are key drivers of biopsy devices market growth.

Hospitals, diagnostic centers, and clinics are increasingly using advanced technology such as vacuum-assisted, MRI-guided, and image-guided biopsy techniques for better results. Advances in precision sampling, image guidance, and safety are driving the growth of these technologies.

In 2025, over 62% of hospitals and diagnostic centres utilized advanced biopsy devices for cancer screening and tissue diagnostics, supporting sustained market expansion and positioning biopsy devices as a cornerstone of modern oncology care.

Biopsy Devices Market Restraints:

• High device costs and limited reimbursement policies in developing regions remain significant barriers to widespread adoption of biopsy devices.

These financial problems may limit access to advanced technologies, especially in low- and middle-income countries. The risks associated with image-guided procedures, such as bleeding, infection, and patient discomfort, also contribute to low acceptance by both doctors and patients. The lack of skilled professionals in emerging economies is another barrier to image-guided procedures. The availability of alternative diagnostic procedures, such as liquid biopsy, is another force that increases competition.

In 2025, over 28% of diagnostic centres reported cost-related barriers to expanding biopsy device usage, underscoring the need for affordability and training initiatives.

Biopsy Devices Market Opportunities:

• Rising adoption of image-guided and MRI-compatible biopsy systems are creating strong opportunities for market expansion.

Opportunities coupled with advancements in vacuum-assisted technologies, Hospitals, diagnostic centres, and specialty clinics are increasingly investing in AI-integrated guidance systems to enhance precision and reduce false negatives. Emerging markets in Asia-Pacific and Latin America offer untapped potential with healthcare modernization and cancer screening initiatives.

In 2025, over 45% of diagnostic centres in Asia-Pacific expanded biopsy device usage, highlighting significant growth prospects and positioning advanced biopsy technologies as a cornerstone of precision medicine and global oncology diagnostics.

Biopsy Devices Market Segmentation Analysis:

• By Product Type, Needle Based Biopsy Guns held the largest market share of 43.25% in 2025, while Biopsy Guidance System are expected to grow at the fastest CAGR of 7.63% during 2026–2035.

• By Guidance Technique, Ultrasound-Guided Biopsy dominated with 32.71% market share in 2025, whereas MRI-Guided Biopsy are projected to record the fastest CAGR of 8.91% through 2026–2035.

• By Application, Breast Biopsy accounted for the highest market share of 36.45% in 2025, while Prostate Biopsy are expected to grow at the fastest CAGR of 20.76% during the forecast period.

• By End User, Hospitals & Clinics dominated with a 53.11% share in 2025, while Diagnostics & Imaging Centres are anticipated to expand at the fastest CAGR of 7.74% through 2026–2035.

By Product Type, Needle-Based Biopsy Devices Dominate While Biopsy Guidance Systems Grow Rapidly:

The Needle Based Biopsy segment held the highest share in the market, and this is because these devices are widely used in the detection of breast, prostate, and lung cancers. These devices are accurate, and they are minimally invasive, hence the reason they hold the highest share in the market.

Biopsy Guidance Systems is the segment with the fastest growth rate, The segment is growing due to increased demand for precision medicine, integration with various imaging modalities like MRI and ultrasound, and adoption of AI-assisted guidance systems. The segment is changing the landscape of biopsy procedures with better accuracy and reduced false negative rates.

By Guidance Technique, Ultrasound-Guided Biopsy Dominates While MRI-Guided Biopsy Grows Rapidly:

Ultrasound-Guided Biopsy segment dominates the market due to its widespread use in breast, thyroid, and soft tissue diagnostics. Its affordability, accessibility, and proven accuracy have made it the preferred choice across hospitals and diagnostic centres, securing the largest share of the guidance technique segment.

MRI-Guided Biopsy is the fastest-growing segment, as growth in this segment is fueled by the demand for precision medicine, an increase in prostate and breast cancer, and technological improvements in MRI-guided biopsy devices. MRI-Guided biopsy is revolutionizing the field of cancer diagnosis with greater accuracy in locating intractable tumors.

By Application, Breast Biopsy Dominates While Prostate Biopsy Grows Rapidly:

Breast Biopsy segment has the highest share in the Breast Biopsy Market, driven by the large prevalence rate of breast cancer worldwide and the popularity of screening programs. Breast biopsy devices are widely used in hospitals and diagnostic centers for cancer diagnosis, thus strengthening the Breast Biopsy segment in the global market.

Prostate Biopsy segment is the fastest-growing and is expected to grow at a strong CAGR. This is because of the increasing rate of prostate cancer and the use of MRI technology. In addition, there is an increasing awareness of the importance of early detection. This segment is growing at a rapid pace, and precision diagnostics are playing an important role in the management of prostate cancer.

By End User, Hospitals & Clinics Dominate While Diagnostic & Imaging Centres Grow Rapidly:

Hospitals & Clinics segment holds the largest share of the biopsy devices market. This is because of high patient volume, sophisticated facilities, and widespread adoption of minimally invasive biopsy procedures. The significance of cancer treatment and screening plays an important role.

Diagnostic & Imaging Centres are the fastest-growing segment, expected to witness a healthy growth rate in terms of CAGR. This is because of the increased demand for outpatient diagnostics, image-guided biopsy procedures, and the trend in the health system towards specialized facilities for diagnosis. This segment is quickly gaining momentum with the rise in precise diagnosis facilities.

Biopsy Devices Market Regional Analysis:

North America Biopsy Devices Market Insights

The North America biopsy devices market dominates globally, driven by rising cancer cases, well-established healthcare infrastructure, and high adoption of minimally invasive diagnostic procedures. Hospitals and diagnostic labs in the U.S. and Canadian regions are increasingly adopting vacuum-assisted, ultrasound-guided, and MRI-guided biopsy devices. The region enjoys a strong reimbursement scenario, skilled medical professionals, and continuous innovations in precise sampling techniques.

Get Customized Report as per Your Business Requirement - Enquiry Now

U.S. Biopsy Devices Market Insights:

The US market is leading in the US biopsy devices market in North America owing to a large patient pool suffering from cancer, a large screening population, and a robust healthcare system. The US market is growing due to a large patient population suffering from breast cancer and prostate cancer, a large number of diagnostic centers, and a supportive reimbursement system.

Asia-Pacific Biopsy Devices Market Insights:

The Asia Pacific market for biopsy devices is the fastest-growing market worldwide. The rising incidence of cancer cases, modernization of healthcare infrastructure, and the increased preference for minimally invasive diagnostic procedures are contributing factors to the high growth rate of the Asia Pacific market. Hospitals and diagnostic centers in India, Japan, and Southeast Asia are increasingly using ultrasound-guided and MRI-guided biopsy devices. Government-led cancer screening programs, improving healthcare infrastructure, and the rising trend of precision medicine are the factors that make the Asia Pacific market the key driver of the global market.

China Biopsy Devices Market Insights:

The China biopsy devices market is a key market in the Asia-Pacific region, driven by the large patient base, increasing prevalence of cancer, and high government focus on early detection schemes. The rapid growth of diagnostic imaging centres, the adoption of advanced technologies like vacuum-assisted biopsy devices, MRI-guided biopsy devices, and healthcare reforms are boosting the market growth in the country. In 2025, the China market contributed a major share of the biopsy device market in the Asia-Pacific region, making it a key market with high growth potential.

Europe Biopsy Devices Market Insights:

The Europe biopsy devices market is one of the prominent markets in the global market. This is because of the presence of a robust cancer screening program, advanced healthcare infrastructure, and the use of minimally invasive diagnostic procedures. Countries such as the U.K., France, and Germany are contributing to the growth of the market in this region. This is because of the high utilization of ultrasound-guided and vacuum-assisted biopsy devices.

Germany Biopsy Devices Market Insights:

Germany biopsy devices market can be considered one of the largest markets in the European region due to the high incidence of breast and prostate cancers. In addition, Germany has a highly developed infrastructure for healthcare and also makes use of image-guided biopsy devices. The hospitals and diagnostic centers are increasingly making use of MRI guidance and vacuum-assisted biopsy devices for diagnostic as well as therapeutic purposes. The government's support for cancer screening and diagnostic procedures has made Germany one of the largest markets for biopsy devices, setting a benchmark for the rest of the markets.

Latin America Biopsy Devices Market Insights:

The Latin American market for biopsy devices is growing steadily, driven by the rising incidence of cancer and development of healthcare infrastructure in countries such as Brazil and Mexico. The use of ultrasound-guidance and needle-based biopsy devices is gaining momentum in the region, although the high cost of devices and limited reimbursement are still hindering the market. Government-backed cancer screening programs and rising investments in diagnostic facilities are providing momentum to the market.

Middle East & Africa Biopsy Devices Market Insights:

The Middle East & Africa biopsy devices market is in its initial stages with significant growth prospects due to the rising incidence of cancer cases, increased access to healthcare services, and the development of modern diagnostic infrastructure. The adoption of minimally invasive procedures is gaining popularity in the region, especially in urban areas such as hospitals and clinics. However, lack of awareness and lack of skilled professionals are impeding the market growth in the Middle East and Africa regions. The development of healthcare infrastructure and the government's initiatives towards cancer detection are likely to boost the market in the region.

Biopsy Devices Market Competitive Landscape:

Hologic Inc, is a global leader in women’s health and diagnostics, with a strong focus on breast cancer detection and biopsy solutions. The company dominates the biopsy devices market through its advanced vacuum-assisted breast biopsy systems and imaging-guided technologies, which are widely adopted in hospitals and diagnostic centres. Hologic’s reputation for innovation, reliability, and precision has positioned it as a trusted partner in oncology diagnostics.

• In 2025, its breast biopsy portfolio accounted for a significant share of global procedures, reinforcing its leadership in minimally invasive cancer diagnostics and patient-centric care.

Becton, Dickinson and Company (BD), is one of the largest medical technology companies worldwide, with a diversified portfolio spanning diagnostics, medical devices, and life sciences. In the biopsy devices market, BD dominates through its needle-based biopsy systems, which are extensively used for breast, lung, and prostate cancer diagnostics. The company’s strength lies in its global distribution network, affordability, and proven clinical efficacy. BD’s acquisition of C.R. Bard further expanded its biopsy product line, solidifying its leadership.

• In 2025, BD’s biopsy devices were utilized across thousands of hospitals and clinics, making it a cornerstone provider in minimally invasive diagnostic solutions.

Cook Group, is a pioneer in minimally invasive medical devices, with a strong presence in biopsy technologies. The company dominates the market through its wide range of biopsy needles and tissue sampling devices, known for precision and safety. Cook’s focus on innovation, clinician training, and patient outcomes has made its products highly preferred in oncology diagnostics worldwide. Its biopsy solutions are particularly strong in lung and liver cancer applications, where accuracy is critical.

• In 2025, Cook Group’s biopsy devices were adopted across leading hospitals and specialty clinics, reinforcing its role as a trusted innovator in diagnostic care.

Biopsy Devices Market Key Players:

Some of the Biopsy Devices Market Companies are:

• Hologic, Inc.

• Becton, Dickinson and Company (BD)

• Cook Group Incorporated

• Argon Medical Devices

• Boston Scientific Corporation

• Gallini Medical

• TSK Laboratory Europe

• B. Braun Melsungen AG

• Cardinal Health, Inc.

• Medtronic plc

• FUJIFILM Holdings Corporation

• INRAD Inc.

• Olympus Corporation

• Merit Medical Systems, Inc.

• IZI Medical Products

• Danaher Corporation

• Devicor Medical Products (part of Leica Biosystems/Danaher)

• C.R. Bard (now part of BD)

• Stryker Corporation

• Siemens Healthineer